UKHealthcare, Pharmacy Services, University of Kentucky, Lexington, Kentucky.
University of Kentucky College of Pharmacy, Pharmacy Practice and Science, Lexington, Kentucky.
Pharmacotherapy. 2019 Mar;39(3):346-354. doi: 10.1002/phar.2231. Epub 2019 Mar 11.
Augmented renal clearance (ARC) is a phenomenon in critically ill patients characterized by increased creatinine clearance and elimination of renally eliminated medications. Patients with severe neurologic injury, sepsis, trauma, and burns have been consistently identified as at risk of ARC, with mean creatinine clearances ranging from 170 ml/minute to more than 300 ml/minute. Several potential mechanisms may contribute to the occurrence of ARC including endogenous responses to increased metabolism and solute production, alterations in neurohormonal balance, and therapeutic maneuvers such as fluid resuscitation. Augmented renal clearance is associated with suboptimal exposure to critical medications, including β-lactams and vancomycin, increasing the risk of treatment failure. Although definitive screening tools are not yet known, critical care pharmacists must be vigilant in recognizing when ARC may be a contributing factor affecting expected treatment outcomes in individual patients. Optimizing dosing strategies in critically ill patients with ARC remains a goal of continued research. The current review discusses the clinical characteristics and methods of identifying patients at risk of ARC, potential mechanisms for ARC, and describes pharmacotherapy dosing considerations in patients with ARC.
增强的肾清除率(ARC)是危重病患者的一种现象,其特征为肌酐清除率增加和肾排泄药物的消除。严重神经损伤、脓毒症、创伤和烧伤的患者一直被认为有 ARC 的风险,平均肌酐清除率从 170ml/min 到 300ml/min 以上。几种潜在的机制可能导致 ARC 的发生,包括对增加的代谢和溶质产生的内源性反应、神经激素平衡的改变以及液体复苏等治疗措施。ARC 与关键药物(包括β-内酰胺类和万古霉素)的暴露不足有关,增加了治疗失败的风险。尽管目前还没有明确的筛查工具,但重症监护药剂师必须警惕 ARC 可能是影响个体患者预期治疗结果的一个因素。优化 ARC 危重病患者的给药策略仍然是持续研究的目标。本综述讨论了识别 ARC 风险患者的临床特征和方法、ARC 的潜在机制,并描述了 ARC 患者的药物治疗剂量考虑因素。